Invention Grant
- Patent Title: Engineered polypeptides having enhanced duration of action
- Patent Title (中): 具有增强的作用持续时间的工程化多肽
-
Application No.: US13852899Application Date: 2013-03-28
-
Publication No.: US09593154B2Publication Date: 2017-03-14
- Inventor: Mary Erickson , David C. Litzinger , Soumitra S. Ghosh , Zijian Guo , Swetha Neravetla , Chengzao Sun , Manoj P. Samant , Odile E. Levy , Abhinandini Sharma , Lala Mamedova , Christopher J. Soares
- Applicant: AMYLIN PHARMACEUTICALS, LLC , ASTRAZENECA PHARMACEUTICALS LP
- Applicant Address: US DE Wilmington US CA San Diego
- Assignee: AstraZeneca Pharmaceuticals LP,Amylin Pharmaceuticals, LLC
- Current Assignee: AstraZeneca Pharmaceuticals LP,Amylin Pharmaceuticals, LLC
- Current Assignee Address: US DE Wilmington US CA San Diego
- Agency: Mintz Levin Cohn Ferris Glovsky and Popeo, P.C.
- Main IPC: C07K14/605
- IPC: C07K14/605 ; A61K47/48 ; C07K14/575

Abstract:
Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including oral administration. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including obesity and overweight, diabetes, dyslipidemia, hyperlipidemia, Alzheimer's disease, fatty liver disease, short bowel syndrome, Parkinson's disease, cardiovascular disease, and other and disorders of the central nervous system.
Public/Granted literature
- US20140107019A1 ENGINEERED POLYPEPTIDES HAVING ENHANCED DURATION OF ACTION Public/Granted day:2014-04-17
Information query